Dulaglutide as a Demethylating Agent to Improve the Outcome of Breast Cancer

References

• Siegel RL , MillerKD , WagleNS , JemalA. Cancer statistics, 2023. Cancer J. Clin.73(1), 17–48 (2023).
   PubMed Web of Science ®Google Scholar
• Giaquinto AN , SungH , MillerKDet al. Breast cancer statistics, 2022. Cancer J. Clin.72(6), 524–541 (2022).
   PubMed Web of Science ®Google Scholar
• Dai X , ChengH , BaiZ , LiJ. Breast cancer cell line classification and its relevance with breast tumor subtyping. J. Cancer8(16), 3131 (2017).
   PubMed Web of Science ®Google Scholar
• Creighton CJ . The molecular profile of luminal B breast cancer. Biol. Target. Ther.6, 289–297 (2012).
   PubMedGoogle Scholar
• Eroles P , BoschA , Pérez-FidalgoJA , LluchA. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat. Rev.38(6), 698–707 (2012).
   PubMed Web of Science ®Google Scholar
• Britt KL , CuzickJ , PhillipsK-A. Key steps for effective breast cancer prevention. Nat. Rev. Cancer20(8), 417–436 (2020).
   PubMed Web of Science ®Google Scholar
• Villanueva L , Álvarez-ErricoD , EstellerM. The contribution of epigenetics to cancer immunotherapy. Trends Immunol.41(8), 676–691 (2020).
   PubMed Web of Science ®Google Scholar
• Moore LD , LeT , FanG. DNA methylation and its basic function. Neuropsychopharmacology38(1), 23–38 (2013).
   PubMed Web of Science ®Google Scholar
• Lapidus RG , FergusonAT , OttavianoYLet al. Methylation of estrogen and progesterone receptor gene 5′CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin. Cancer Res.2(5), 805–810 (1996).
   PubMed Web of Science ®Google Scholar
• Lombaerts M , van WezelT , PhilippoKet al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br. J. Cancer94(5), 661–671 (2006).
   PubMed Web of Science ®Google Scholar
• Casalino L , VerdeP. Multifaceted roles of DNA methylation in neoplastic transformation, from tumor suppressors to EMT and metastasis. Genes11(8), 922 (2020).
   PubMed Web of Science ®Google Scholar
• Romero-Garcia S , Prado-GarciaH , Carlos-ReyesA. Role of DNA methylation in the resistance to therapy in solid tumors. Front. Oncol.10, 1152 (2020).
   PubMedGoogle Scholar
• Jin Z , LiuY. DNA methylation in human diseases. Genes Dis.5(1), 1–8 (2018).
   PubMed Web of Science ®Google Scholar
• Hall E , DayehT , KirkpatrickCL , WollheimCB , DekkerNitert M , LingC. DNA methylation of the glucagon-like peptide 1 receptor (GLP1R) in human pancreatic islets. BMC Med. Genet.14, 1–7 (2013).
   PubMed Web of Science ®Google Scholar
• Volkov P , BacosK , OforiJKet al. Whole-genome bisulfite sequencing of human pancreatic islets reveals novel differentially methylated regions in type 2 diabetes pathogenesis. Diabetes66(4), 1074–1085 (2017).
   PubMed Web of Science ®Google Scholar
• Ling C , BacosK , RönnT. Epigenetics of type 2 diabetes mellitus and weight change – a tool for precision medicine?Nat. Rev. Endocrinol.18(7), 433–448 (2022).
   PubMed Web of Science ®Google Scholar
• Ahmed SAH , AnsariSA , Mensah-BrownEP , EmeraldBS. The role of DNA methylation in the pathogenesis of type 2 diabetes mellitus. Clin. Epigenet.12, 1–23 (2020).
   Web of Science ®Google Scholar
• Zhao J , YangS , ShuBet al. Transient high glucose causes persistent vascular dysfunction and delayed wound healing by the DNMT1-mediated Ang-1/NF-κB pathway. J. Investig. Dermatol.141(6), 1573–1584 (2021).
   PubMed Web of Science ®Google Scholar
• Boyle P , BoniolM , KoechlinAet al. Diabetes and breast cancer risk: a meta-analysis. Br. J. Cancer107(9), 1608–1617 (2012).
   PubMed Web of Science ®Google Scholar
• Samuel SM , VargheseE , VargheseS , BüsselbergD. Challenges and perspectives in the treatment of diabetes associated breast cancer. Cancer Treat. Rev.70, 98–111 (2018).
   PubMed Web of Science ®Google Scholar
• Butler PC , ElashoffM , ElashoffR , GaleEA. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?Diabetes Care36(7), 2118–2125 (2013).
   PubMed Web of Science ®Google Scholar
• Ligumsky H , WolfI , IsraeliSet al. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res. Treat.132, 449–461 (2012).
   PubMed Web of Science ®Google Scholar
• Chequin A , CostaLE , de CamposFFet al. Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chemico-Biol. Interact.349, 109641 (2021).
   PubMed Web of Science ®Google Scholar
• Glaesner W , MarkVick A , MillicanRet al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes/Metab. Res. Rev.26(4), 287–296 (2010).
   PubMed Web of Science ®Google Scholar
• Yu M , BenjaminMM , SrinivasanSet al. Battle of GLP-1 delivery technologies. Adv. Drug Deliv. Rev.130, 113–130 (2018).
   PubMed Web of Science ®Google Scholar
• Pushpakom S , IorioF , EyersPAet al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov.18(1), 41–58 (2019).
   PubMed Web of Science ®Google Scholar
• Shi Y , YeP , LongX. Differential expression profiles of the transcriptome in breast cancer cell lines revealed by next generation sequencing. Cell. Physiol. Biochem.44(2), 804–816 (2017).
   PubMedGoogle Scholar
• Stamps AC , DaviesSC , BurmanJ , O’HareMJ. Analysis of proviral integration in human mammary epithelial cell lines immortalized by retroviral infection with a temperature-sensitive SV40 T-antigen construct. Int. J. Cancer57(6), 865–874 (1994).
   PubMed Web of Science ®Google Scholar
• Neve RM , ChinK , FridlyandJet al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell10(6), 515–527 (2006).
   PubMed Web of Science ®Google Scholar
• Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods65(1–2), 55–63 (1983).
   PubMed Web of Science ®Google Scholar
• Seniski GG , CamargoAA , IerardiDFet al. ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma. BMC Cancer9(1), 1–10 (2009).
   PubMedGoogle Scholar
• National Research Council . Guide for the care and use of laboratory animals (2010). www.ncbi.nlm.nih.gov/books/NBK54050/
   Google Scholar
• Mishra S , TamtaAK , SarikhaniMet al. Subcutaneous Ehrlich Ascites Carcinoma mice model for studying cancer-induced cardiomyopathy. Sci. Rep.8(1), 5599 (2018).
   PubMedGoogle Scholar
• Stone A , ZotenkoE , LockeWJet al. DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer. Nat. Comm.6(1), 7758 (2015).
   PubMedGoogle Scholar
• Manica G , RibeiroCF , de OliveiraMAet al. Down regulation of ADAM33 as a predictive biomarker of aggressive breast cancer. Sci. Rep.7(1), 1–13 (2017).
   PubMedGoogle Scholar
• Panjarian S , IssaJ-PJ. The roles of DNA demethylases in triple-negative breast cancer. Pharmaceuticals14(7), 628 (2021).
   Web of Science ®Google Scholar
• Howell PM Jr , LiuZ , KhongHT. Demethylating agents in the treatment of cancer. Pharmaceuticals3(7), 2022–2044 (2010).
   Google Scholar
• Serrano-Gomez SJ , MaziveyiM , AlahariSK. Regulation of epithelial–mesenchymal transition through epigenetic and post-translational modifications. Mol. Cancer15(1), 1–14 (2016).
   PubMedGoogle Scholar
• Song Y , YeM , ZhouJ , WangZ , ZhuX. Targeting E-cadherin expression with small molecules for digestive cancer treatment. Am. J. Translat. Res.11(7), 3932 (2019).
   PubMed Web of Science ®Google Scholar
• Sappok A , MahlknechtU. Ribavirin restores ESR1 gene expression and tamoxifen sensitivity in ESR1 negative breast cancer cell lines. Clin. Epigenet.3(1), 1–9 (2011).
   PubMedGoogle Scholar
• Thiery JP , SleemanJP. Complex networks orchestrate epithelial–mesenchymal transitions. Nat. Rev. Mol. Cell Biol.7(2), 131–142 (2006).
   PubMed Web of Science ®Google Scholar
• Garg M . Epithelial plasticity, autophagy and metastasis: potential modifiers of the crosstalk to overcome therapeutic resistance. Stem Cell Rev. Rep.16(3), 503–510 (2020).
   PubMed Web of Science ®Google Scholar
• Lamouille S , XuJ , DerynckR. Molecular mechanisms of epithelial–mesenchymal transition. Nat. Rev. Mol. Cell Biol.15(3), 178–196 (2014).
   PubMed Web of Science ®Google Scholar
• Dongre A , WeinbergRA. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol.20(2), 69–84 (2019).
   PubMed Web of Science ®Google Scholar
• Topper MJ , VazM , MarroneKA , BrahmerJR , BaylinSB. The emerging role of epigenetic therapeutics in immuno-oncology. Nat. Rev. Clin. Oncol.17(2), 75–90 (2020).
   PubMed Web of Science ®Google Scholar